Parker Institute for Cancer Immunotherapy to Showcase 50+ Studies at ASCO 2026
Event summary
- Parker Institute for Cancer Immunotherapy (PICI) will present over 50 studies at ASCO 2026, spanning glioblastoma, melanoma, prostate, breast, lung, and urothelial cancers.
- New data includes updated readouts on CAR T-cell and TIL-based therapies, personalized neoantigen vaccine strategies, and immune profiling platforms.
- PICI will unveil latest results from its RADIOHEAD pan-cancer cohort, featuring multimodal immunoprofiling to predict immunotherapy response and toxicity.
- Inaugural Conquer Cancer PICI Endowed Young Investigator Award to be announced, recognizing early-career clinical oncology investigators.
The big picture
PICI's extensive presence at ASCO 2026 underscores the growing importance of collaborative, data-driven approaches in cancer immunotherapy. The institute's model of uniting top cancer centers to advance clinical testing and commercialization reflects a broader industry shift towards integrated, high-impact research. With over 1,000 investigators supported and 17 biotech ventures in its portfolio, PICI is positioning itself as a key player in turning scientific discoveries into accessible treatments.
What we're watching
- Clinical Momentum
- Whether the updated data from glioblastoma, melanoma, and other cancer studies will demonstrate meaningful progress in treatment outcomes.
- Collaborative Model
- How PICI's integrated network approach will continue to drive high-risk, high-reward science and accelerate the development of breakthrough immune therapies.
- Predictive Platforms
- The pace at which multimodal immunoprofiling platforms like RADIOHEAD will become standard in predicting immunotherapy response and toxicity across cancer types.
Related topics